Form D · Biotechnology
xMD Diagnostics, Inc.
Annapolis, MD · CIK 0001698878
Offering snapshot reported Oct 29, 2018 · SEC filing
- Reported sold
- $500K Offering amount: $3.5M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Oct 17, 2018 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 29, 2018 | Initial | $500,000 | No comparison | 1 | SEC filing |
| Mar 29, 2017 | Initial | $175,000 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-324523
Offering also includes the conversion of previously issued promissory notes into preferred shares of the Issuer.
Source: Form D, filed Oct 29, 2018. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Michael Emmert Buck | Executive |
| Al Fleury | Executive |
| Ting Pau Oei | Director, Executive |
| Stephen R. Ritterbush | Director, Executive |
| Benjamin Shapiro | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
415 Fourth Street, Suite 201
Annapolis, MD, 21401
Annapolis, MD, 21401